Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.56 -2.8%	$6.13	$4.35 ▼ $12.38	$339.31M	0.45	208,646 shs	122,903 shs
BNTC Benitec Biopharma	$12.44 -6.1%	$14.14	$7.05 ▼ $17.15	$347.81M	0.37	57,503 shs	67,884 shs
MREO Mereo BioPharma Group	$1.71 -0.6%	$2.50	$1.57 ▼ $5.02	$273.48M	0.46	1.32 million shs	2.67 million shs
SLN Silence Therapeutics	$6.49 +3.3%	$5.33	$1.97 ▼ $22.47	N/A	1.39	293,724 shs	134,007 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-2.81%	+4.96%	+2.18%	+21.48%	-27.03%
BNTC Benitec Biopharma	-6.11%	-1.43%	-24.51%	-8.86%	+21.96%
MREO Mereo BioPharma Group	-0.58%	-39.58%	-38.04%	-19.72%	-58.80%
SLN Silence Therapeutics	+3.34%	+9.81%	+21.76%	+123.79%	-68.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.5705 of 5 stars	3.6	1.0	3.3	3.3	0.0
BNTC Benitec Biopharma	1.4576 of 5 stars	3.6	1.0	1.9	0.8	0.0
MREO Mereo BioPharma Group	1.5624 of 5 stars	3.6	1.0	1.5	1.7	0.0
SLN Silence Therapeutics	1.7097 of 5 stars	3.4	1.0	1.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	235.37% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	91.59% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	321.05% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	421.31% Upside

Current Analyst Ratings Breakdown

Latest SLN, MREO, BNTC, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$4.68 per share	N/A
MREO Mereo BioPharma Group	$10M	27.19	N/A	N/A	$0.39 per share	4.38
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/15/2025 (Estimated)

Latest SLN, MREO, BNTC, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
BNTC Benitec Biopharma	0.01	14.80	14.80
MREO Mereo BioPharma Group	N/A	8.92	8.92
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
BNTC Benitec Biopharma	52.19%
MREO Mereo BioPharma Group	62.83%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
BNTC Benitec Biopharma	1.30%
MREO Mereo BioPharma Group	5.50%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

SLN, MREO, BNTC, and AURA Headlines

Recent News About These Companies

Silence Therapeutics (NASDAQ:SLN) Stock Rating Lowered by Wall Street Zen

July 14 at 2:31 AM | americanbankingnews.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.comB

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

February 11, 2025 | markets.businessinsider.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

Goldman Sachs cuts Silence Therapeutics stock rating to Sell

February 11, 2025 | msn.com

(SLN) Investment Analysis

January 17, 2025 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, MREO, BNTC, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.56 -0.19 (-2.81%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$6.59 +0.03 (+0.47%)

As of 07:02 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$12.44 -0.81 (-6.11%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$12.46 +0.02 (+0.12%)

As of 07/15/2025 04:24 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Mereo BioPharma Group NASDAQ:MREO

$1.71 -0.01 (-0.58%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.68 -0.03 (-2.05%)

As of 07:33 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Silence Therapeutics NASDAQ:SLN

$6.49 +0.21 (+3.34%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$6.44 -0.04 (-0.69%)

As of 07/15/2025 07:56 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time